Research Analysts Issue Forecasts for BMY Q1 Earnings
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week
A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
Big Pharma: Seeking Alpha Analysts vs. Wall Street
Following a lackluster 2024, shares of major drug markers kicked off 2025 with an upbeat quarterly results reading.
NICE green lights two blood cancer therapies for NHS use
BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
Hosted on MSN2d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Bristol Myers Squibb Names New GC as Legal Chief Retires
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
$1.3M Settlement: Focus Groups Helped Craft the Deal
The case was made more complex because the plaintiff, who was 36 at the time of the crash, had prior back problems.
Healio3d
Q&A: ‘Everyone benefits’ from noninvasive, individualized monitoring in pediatric IBD
Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools ...